MAPK1 and sinus histiocytosis with massive lymphadenopathy: Targeted therapy with mitogen-activated protein kinase inhibitors is under investigation in those with MAPK/ERK pathway alterations.36,39 In most cases, RDD has a benign course and treatment is not required.